Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
4.2 CHF
−4.79 M CHF
90.14 M CHF
7.09 M
About COSMO PHARM N
Sector
CEO
Giovanni di Napoli
Headquarters
Dublin
Website
Founded
2016
ISIN
NL0011832936
FIGI
BBG00CWX1FP3
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of COPN is 63.7 CHF — it has increased by 4.08% in the past 24 hours. Watch COSMO PHARM N stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange COSMO PHARM N stocks are traded under the ticker COPN.
COPN stock has risen by 7.97% compared to the previous week, the month change is a 2.74% rise, over the last year COSMO PHARM N has showed a 24.90% increase.
We've gathered analysts' opinions on COSMO PHARM N future price: according to them, COPN price has a max estimate of 132.42 CHF and a min estimate of 78.95 CHF. Watch COPN chart and read a more detailed COSMO PHARM N stock forecast: see what analysts think of COSMO PHARM N and suggest that you do with its stocks.
COPN reached its all-time high on Jul 9, 2014 with the price of 193.7 CHF, and its all-time low was 11.0 CHF and was reached on Dec 12, 2008. View more price dynamics on COPN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
COPN stock is 1.59% volatile and has beta coefficient of 0.64. Track COSMO PHARM N stock price on the chart and check out the list of the most volatile stocks — is COSMO PHARM N there?
Today COSMO PHARM N has the market capitalization of 1.02 B, it has increased by 2.51% over the last week.
Yes, you can track COSMO PHARM N financials in yearly and quarterly reports right on TradingView.
COSMO PHARM N is going to release the next earnings report on Mar 19, 2025. Keep track of upcoming events with our Earnings Calendar.
COPN net income for the last half-year is 73.07 M CHF, while the previous report showed −6.15 M CHF of net income which accounts for 1.29 K% change. Track more COSMO PHARM N financial stats to get the full picture.
Yes, COPN dividends are paid annually. The last dividend per share was 1.95 CHF. As of today, Dividend Yield (TTM)% is 3.06%. Tracking COSMO PHARM N dividends might help you take more informed decisions.
As of Dec 30, 2024, the company has 325.00 employees. See our rating of the largest employees — is COSMO PHARM N on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. COSMO PHARM N EBITDA is 94.77 M CHF, and current EBITDA margin is 20.43%. See more stats in COSMO PHARM N financial statements.
Like other stocks, COPN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade COSMO PHARM N stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So COSMO PHARM N technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating COSMO PHARM N stock shows the sell signal. See more of COSMO PHARM N technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.